BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23701280)

  • 1. Multimodality treatment for poorly differentiated neuroendocrine head and neck carcinomas--a single institution experience.
    Görner M; Brasch F; Hirnle P; Gehl HB; Scholtz LU; Wegehenkel K; Sudhoff H
    Eur J Cancer Care (Engl); 2013 Sep; 22(5):648-52. PubMed ID: 23701280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy.
    Zivanovic O; Leitao MM; Park KJ; Zhao H; Diaz JP; Konner J; Alektiar K; Chi DS; Abu-Rustum NR; Aghajanian C
    Gynecol Oncol; 2009 Mar; 112(3):590-3. PubMed ID: 19110302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of surgical resection after induction chemotherapy for patients with T4b squamous cell head and neck cancer.
    Rivera F; Eugenia Vega-Villegas M; López C; Francisca López-Brea M; Rubio A; Del Valle A; García-Reija F; García-Montesinos B; Rodríguez-Iglesias J; Hinojo C; Márquez R; Angel Alonso-Bermejo M; Salcedo M; Blanco Y; Vega N; López-Tarruella S; Sanz-Ortiz J
    Acta Oncol; 2008; 47(8):1584-9. PubMed ID: 18607841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of definitive chemoradiotherapy in patients with resectable small cell neuroendocrine carcinoma of the esophagus.
    Katada C; Komori S; Yoshida T; Kawakami S; Watanabe A; Ishido K; Azuma M; Wada T; Hosoda K; Yamashita K; Hiki N; Tanabe S; Ishiyama H; Koizumi W
    Esophagus; 2020 Apr; 17(2):135-140. PubMed ID: 31321580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
    Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
    Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
    Choi YJ; Chung JS; Shin HJ; Cho GJ; Wang SG; Lee BJ; Cho BM; Joo YD; Sohn CH
    J Laryngol Otol; 2008 Aug; 122(8):848-53. PubMed ID: 18047761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999.
    Dunphy FR; Dunleavy TL; Harrison BR; Trinkaus KM; Kim HJ; Stack BC; Needles B; Boyd JH
    Cancer; 2001 Mar; 91(5):940-8. PubMed ID: 11251945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. Results in 9 cases.
    Bhattacharyya N; Thornton AF; Joseph MP; Goodman ML; Amrein PC
    Arch Otolaryngol Head Neck Surg; 1997 Jan; 123(1):34-40. PubMed ID: 9006501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
    Chang PM; Chen PM; Chu PY; Wang LW; Tai SK; Tsai TL; Huang JL; Wang YF; Chang SY; Yang MH
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):9-17. PubMed ID: 18343925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
    Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY
    Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
    Hainsworth JD; Spigel DR; Litchy S; Greco FA
    J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of Chemotherapy and Radiation Dose After Microscopically Incomplete Resection of Stage III/IV Head and Neck Cancer.
    Seidl D; Janssen S; Strojan P; Hakim SG; Wollenberg B; Schild SE; Rades D
    Anticancer Res; 2016 May; 36(5):2487-91. PubMed ID: 27127162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism.
    Weisman RA; Christen R; Los G; Jones V; Kerber C; Seagren S; Glassmeyer S; Orloff LA; Wong W; Kirmani S; Howell S
    Otolaryngol Head Neck Surg; 1998 May; 118(5):597-602. PubMed ID: 9591856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of chemotherapy in the treatment of head and neck cancer.
    Inuyama Y; Fukuda S; Furuta Y; Yagi K; Nagahashi T; Chida E; Shirato H; Fujii M; Kanzaki J
    Gan To Kagaku Ryoho; 1997 May; 24 Suppl 1():52-9. PubMed ID: 9210888
    [No Abstract]   [Full Text] [Related]  

  • 15. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
    Klem ML; Mechalakos JG; Wolden SL; Zelefsky MJ; Singh B; Kraus D; Shaha A; Shah J; Pfister DG; Lee NY
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1100-7. PubMed ID: 17980501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
    Haraf DJ; Rosen FR; Stenson K; Argiris A; Mittal BB; Witt ME; Brockstein BE; List MA; Portugal L; Pelzer H; Weichselbaum RR; Vokes EE
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5936-43. PubMed ID: 14676118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience.
    Olsen IH; Langer SW; Jepsen I; Assens M; Federspiel B; Hasselby JP; Hansen CP; Kjaer A; Knigge U
    Acta Oncol; 2012 Jan; 51(1):97-100. PubMed ID: 21615243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In squamous cell head and neck cancer: which platinum, how much and how often?
    Nwizu T; Adelstein DJ
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1033-9. PubMed ID: 24998393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
    Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH
    Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
    Adelstein DJ; Saxton JP; Rybicki LA; Esclamado RM; Wood BG; Strome M; Lavertu P; Lorenz RR; Carroll MA
    J Clin Oncol; 2006 Mar; 24(7):1064-71. PubMed ID: 16505425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.